Pain Management Drugs Market By Drug Class , By Indication By Pain Type : Global Opportunity Analysis and Industry Forecast, 2024-2033

Description

Pain Management Drugs Market

The pain management drugs market was valued at $72.6 billion in 2023 and is projected to reach $109.6 billion by 2033, growing at a CAGR of 4.2% from 2024 to 2033.

A pain management drug is medication prescribed for the alleviation of pain ranging from moderate discomfort to severe distress. The formulation of pain management drugs comprises of different drug class, including opioids, antidepressants or acetaminophen. These medications target diverse pain types, including musculoskeletal, neuropathic, and inflammatory pain. The mechanisms pertaining to the functioning of pain management drug are diverse such as lowering of inflammation, inhibition of pain signals in the nervous system, or alteration of brain chemistry to modulate the perception of pain.

Increase in the prevalence of lifestyle and chronic diseases such as stroke, heart disease, type II diabetes, and cancer is driving the pain management drugs market. In addition, advancements in drug formulations and delivery methods such as extended-release formulations with reduced dosing frequency are boosting the demand for the drugs as they enhance patient compliance & treatment outcomes. In recent times, explorations in nanotherapeutics are trending in the market as nanoparticles are anticipated to possess the capability of precisely identifying the target and offering long-term efficacy in significantly low dosage.

However, the severe side-effects of pain management drugs; including cardiovascular events, gastrointestinal bleeding, sedation, renal impairment, and respiratory depression; limit their consumption, hence presenting challenges for market expansion. To eliminate the hazards of conventional drugs, natural alternatives are being explored as they have potentially minimal to no side-effects. For instance, Kratom, a herbal substance obtained from the Mitragyna speciosa tree, is being utilized as an alternative to opioid drugs. Kratom medications have proved to be highly effective in providing relief from chronic pain conditions such as fibromyalgia & arthritis and neuropathic pain.

Segment Review

The pain management drugs market is segmented into drug class, indication, pain type, and region. On the basis of drug class, the market is divided into NSAIDs, anesthetics, anticonvulsants, anti-migraine agents, antidepressants, opioids, and nonnarcotic analgesics. As per indication, it is classified into arthritic pain, neuropathic pain, cancer pain, chronic back pain, postoperative pain, migraine, fibromyalgia, muscle sprain/strain, bone fracture, acute appendicitis, and others. By pain type, it is bifurcated into chronic pain and acute pain. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

On the basis of drug class, the opioids segment is expected to dominate the market during the forecast period.

As per indication, the postoperative pain segment is predicted to be the highest shareholder by 2033.

By pain type, the chronic pain segment is anticipated to lead the market during the forecast period.

Region wise, North America is projected to be the highest revenue generator by 2033.

Competition Analysis

The major players operating in the global pain management drugs market include Novartis AG, Eli Lilly & Company, Abbott Laboratories, Endo Health Solutions, Inc., Purdue Pharma L.P., Pfizer, Inc., Viatris Inc., Merck & Co. Inc., Johnson & Johnson, and GlaxoSmithKline Plc. These players have adopted various key developmental strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the market.

Additional benefits you will get with this purchase are:

Quarterly Update and* (only available with a corporate license, on listed price)
5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
Free Upcoming Version on the Purchase of Five and Enterprise User License.
16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
Free data Pack on the Five and Enterprise User License. (Excel version of the report)
Free Updated report if the report is 6-12 months old or older.
24-hour priority response*
Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

Regulatory Guidelines
Additional company profiles with specific to client's interest
Additional country or region analysis- market size and forecast
Expanded list for Company Profiles
Historic market data
Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Drug Class

NSAIDs
Anesthetics
Anticonvulsants
Anti-migraine Agents
Antidepressants
Opioids
Nonnarcotic Analgesics

By Indication

Arthritic Pain
Neuropathic Pain
Cancer Pain
Chronic Back Pain
Postoperative Pain
Migraine
Fibromyalgia
Muscle Sprain/Strain
Bone Fracture
Acute Appendicitis
Others

By Pain Type

Chronic Pain
Acute Pain

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA

Key Market Players:

Novartis AG
Eli Lilly & Company
Abbott Laboratories
Endo Health Solutions, Inc.
Purdue Pharma L.P.
Pfizer, Inc.
Viatris Inc.
Merck & Co. Inc.
Johnson & Johnson
GlaxoSmithKline Plc

Product Code: A00309

CHAPTER 1: INTRODUCTION

1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
- 1.4.1. Primary Research
- 1.4.2. Secondary Research
- 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

3.1. Market Definition and Scope
3.2. Key Findings
- 3.2.1. Top Investment Pockets
- 3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
- 3.3.1. Bargaining Power of Suppliers
- 3.3.2. Threat of New Entrants
- 3.3.3. Threat of Substitutes
- 3.3.4. Competitive Rivalry
- 3.3.5. Bargaining Power among Buyers
3.4. Market Dynamics
- 3.4.1. Drivers
- 3.4.2. Restraints
- 3.4.3. Opportunities

CHAPTER 4: PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS

4.1. Market Overview
- 4.1.1 Market Size and Forecast, By Drug Class
4.2. NSAIDs
- 4.2.1. Key Market Trends, Growth Factors and Opportunities
- 4.2.2. Market Size and Forecast, By Region
- 4.2.3. Market Share Analysis, By Country
4.3. Anesthetics
- 4.3.1. Key Market Trends, Growth Factors and Opportunities
- 4.3.2. Market Size and Forecast, By Region
- 4.3.3. Market Share Analysis, By Country
4.4. Anticonvulsants
- 4.4.1. Key Market Trends, Growth Factors and Opportunities
- 4.4.2. Market Size and Forecast, By Region
- 4.4.3. Market Share Analysis, By Country
4.5. Anti-migraine Agents
- 4.5.1. Key Market Trends, Growth Factors and Opportunities
- 4.5.2. Market Size and Forecast, By Region
- 4.5.3. Market Share Analysis, By Country
4.6. Antidepressants
- 4.6.1. Key Market Trends, Growth Factors and Opportunities
- 4.6.2. Market Size and Forecast, By Region
- 4.6.3. Market Share Analysis, By Country
4.7. Opioids
- 4.7.1. Key Market Trends, Growth Factors and Opportunities
- 4.7.2. Market Size and Forecast, By Region
- 4.7.3. Market Share Analysis, By Country
4.8. Nonnarcotic Analgesics
- 4.8.1. Key Market Trends, Growth Factors and Opportunities
- 4.8.2. Market Size and Forecast, By Region
- 4.8.3. Market Share Analysis, By Country

CHAPTER 5: PAIN MANAGEMENT DRUGS MARKET, BY INDICATION

5.1. Market Overview
- 5.1.1 Market Size and Forecast, By Indication
5.2. Arthritic Pain
- 5.2.1. Key Market Trends, Growth Factors and Opportunities
- 5.2.2. Market Size and Forecast, By Region
- 5.2.3. Market Share Analysis, By Country
5.3. Neuropathic Pain
- 5.3.1. Key Market Trends, Growth Factors and Opportunities
- 5.3.2. Market Size and Forecast, By Region
- 5.3.3. Market Share Analysis, By Country
5.4. Cancer Pain
- 5.4.1. Key Market Trends, Growth Factors and Opportunities
- 5.4.2. Market Size and Forecast, By Region
- 5.4.3. Market Share Analysis, By Country
5.5. Chronic Back Pain
- 5.5.1. Key Market Trends, Growth Factors and Opportunities
- 5.5.2. Market Size and Forecast, By Region
- 5.5.3. Market Share Analysis, By Country
5.6. Postoperative Pain
- 5.6.1. Key Market Trends, Growth Factors and Opportunities
- 5.6.2. Market Size and Forecast, By Region
- 5.6.3. Market Share Analysis, By Country
5.7. Migraine
- 5.7.1. Key Market Trends, Growth Factors and Opportunities
- 5.7.2. Market Size and Forecast, By Region
- 5.7.3. Market Share Analysis, By Country
5.8. Fibromyalgia
- 5.8.1. Key Market Trends, Growth Factors and Opportunities
- 5.8.2. Market Size and Forecast, By Region
- 5.8.3. Market Share Analysis, By Country
5.9. Muscle Sprain/Strain
- 5.9.1. Key Market Trends, Growth Factors and Opportunities
- 5.9.2. Market Size and Forecast, By Region
- 5.9.3. Market Share Analysis, By Country
5.10. Bone Fracture
- 5.10.1. Key Market Trends, Growth Factors and Opportunities
- 5.10.2. Market Size and Forecast, By Region
- 5.10.3. Market Share Analysis, By Country
5.11. Acute Appendicitis
- 5.11.1. Key Market Trends, Growth Factors and Opportunities
- 5.11.2. Market Size and Forecast, By Region
- 5.11.3. Market Share Analysis, By Country
5.12. Others
- 5.12.1. Key Market Trends, Growth Factors and Opportunities
- 5.12.2. Market Size and Forecast, By Region
- 5.12.3. Market Share Analysis, By Country

CHAPTER 6: PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE

6.1. Market Overview
- 6.1.1 Market Size and Forecast, By Pain Type
6.2. Chronic Pain
- 6.2.1. Key Market Trends, Growth Factors and Opportunities
- 6.2.2. Market Size and Forecast, By Region
- 6.2.3. Market Share Analysis, By Country
6.3. Acute Pain
- 6.3.1. Key Market Trends, Growth Factors and Opportunities
- 6.3.2. Market Size and Forecast, By Region
- 6.3.3. Market Share Analysis, By Country

CHAPTER 7: PAIN MANAGEMENT DRUGS MARKET, BY REGION

7.1. Market Overview
- 7.1.1 Market Size and Forecast, By Region
7.2. North America
- 7.2.1. Key Market Trends and Opportunities
- 7.2.2. Market Size and Forecast, By Drug Class
- 7.2.3. Market Size and Forecast, By Indication
- 7.2.4. Market Size and Forecast, By Pain Type
- 7.2.5. Market Size and Forecast, By Country
- 7.2.6. U.S. Pain Management Drugs Market
  - 7.2.6.1. Market Size and Forecast, By Drug Class
  - 7.2.6.2. Market Size and Forecast, By Indication
  - 7.2.6.3. Market Size and Forecast, By Pain Type
- 7.2.7. Canada Pain Management Drugs Market
  - 7.2.7.1. Market Size and Forecast, By Drug Class
  - 7.2.7.2. Market Size and Forecast, By Indication
  - 7.2.7.3. Market Size and Forecast, By Pain Type
- 7.2.8. Mexico Pain Management Drugs Market
  - 7.2.8.1. Market Size and Forecast, By Drug Class
  - 7.2.8.2. Market Size and Forecast, By Indication
  - 7.2.8.3. Market Size and Forecast, By Pain Type
7.3. Europe
- 7.3.1. Key Market Trends and Opportunities
- 7.3.2. Market Size and Forecast, By Drug Class
- 7.3.3. Market Size and Forecast, By Indication
- 7.3.4. Market Size and Forecast, By Pain Type
- 7.3.5. Market Size and Forecast, By Country
- 7.3.6. Germany Pain Management Drugs Market
  - 7.3.6.1. Market Size and Forecast, By Drug Class
  - 7.3.6.2. Market Size and Forecast, By Indication
  - 7.3.6.3. Market Size and Forecast, By Pain Type
- 7.3.7. France Pain Management Drugs Market
  - 7.3.7.1. Market Size and Forecast, By Drug Class
  - 7.3.7.2. Market Size and Forecast, By Indication
  - 7.3.7.3. Market Size and Forecast, By Pain Type
- 7.3.8. UK Pain Management Drugs Market
  - 7.3.8.1. Market Size and Forecast, By Drug Class
  - 7.3.8.2. Market Size and Forecast, By Indication
  - 7.3.8.3. Market Size and Forecast, By Pain Type
- 7.3.9. Italy Pain Management Drugs Market
  - 7.3.9.1. Market Size and Forecast, By Drug Class
  - 7.3.9.2. Market Size and Forecast, By Indication
  - 7.3.9.3. Market Size and Forecast, By Pain Type
- 7.3.10. Spain Pain Management Drugs Market
  - 7.3.10.1. Market Size and Forecast, By Drug Class
  - 7.3.10.2. Market Size and Forecast, By Indication
  - 7.3.10.3. Market Size and Forecast, By Pain Type
- 7.3.11. Rest of Europe Pain Management Drugs Market
  - 7.3.11.1. Market Size and Forecast, By Drug Class
  - 7.3.11.2. Market Size and Forecast, By Indication
  - 7.3.11.3. Market Size and Forecast, By Pain Type
7.4. Asia-Pacific
- 7.4.1. Key Market Trends and Opportunities
- 7.4.2. Market Size and Forecast, By Drug Class
- 7.4.3. Market Size and Forecast, By Indication
- 7.4.4. Market Size and Forecast, By Pain Type
- 7.4.5. Market Size and Forecast, By Country
- 7.4.6. Japan Pain Management Drugs Market
  - 7.4.6.1. Market Size and Forecast, By Drug Class
  - 7.4.6.2. Market Size and Forecast, By Indication
  - 7.4.6.3. Market Size and Forecast, By Pain Type
- 7.4.7. China Pain Management Drugs Market
  - 7.4.7.1. Market Size and Forecast, By Drug Class
  - 7.4.7.2. Market Size and Forecast, By Indication
  - 7.4.7.3. Market Size and Forecast, By Pain Type
- 7.4.8. India Pain Management Drugs Market
  - 7.4.8.1. Market Size and Forecast, By Drug Class
  - 7.4.8.2. Market Size and Forecast, By Indication
  - 7.4.8.3. Market Size and Forecast, By Pain Type
- 7.4.9. Australia Pain Management Drugs Market
  - 7.4.9.1. Market Size and Forecast, By Drug Class
  - 7.4.9.2. Market Size and Forecast, By Indication
  - 7.4.9.3. Market Size and Forecast, By Pain Type
- 7.4.10. South Korea Pain Management Drugs Market
  - 7.4.10.1. Market Size and Forecast, By Drug Class
  - 7.4.10.2. Market Size and Forecast, By Indication
  - 7.4.10.3. Market Size and Forecast, By Pain Type
- 7.4.11. Rest of Asia-Pacific Pain Management Drugs Market
  - 7.4.11.1. Market Size and Forecast, By Drug Class
  - 7.4.11.2. Market Size and Forecast, By Indication
  - 7.4.11.3. Market Size and Forecast, By Pain Type
7.5. LAMEA
- 7.5.1. Key Market Trends and Opportunities
- 7.5.2. Market Size and Forecast, By Drug Class
- 7.5.3. Market Size and Forecast, By Indication
- 7.5.4. Market Size and Forecast, By Pain Type
- 7.5.5. Market Size and Forecast, By Country
- 7.5.6. Brazil Pain Management Drugs Market
  - 7.5.6.1. Market Size and Forecast, By Drug Class
  - 7.5.6.2. Market Size and Forecast, By Indication
  - 7.5.6.3. Market Size and Forecast, By Pain Type
- 7.5.7. Saudi Arabia Pain Management Drugs Market
  - 7.5.7.1. Market Size and Forecast, By Drug Class
  - 7.5.7.2. Market Size and Forecast, By Indication
  - 7.5.7.3. Market Size and Forecast, By Pain Type
- 7.5.8. South Africa Pain Management Drugs Market
  - 7.5.8.1. Market Size and Forecast, By Drug Class
  - 7.5.8.2. Market Size and Forecast, By Indication
  - 7.5.8.3. Market Size and Forecast, By Pain Type
- 7.5.9. Rest of LAMEA Pain Management Drugs Market
  - 7.5.9.1. Market Size and Forecast, By Drug Class
  - 7.5.9.2. Market Size and Forecast, By Indication
  - 7.5.9.3. Market Size and Forecast, By Pain Type

CHAPTER 8: COMPETITIVE LANDSCAPE

8.1. Introduction
8.2. Top Winning Strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top Player Positioning, 2023

CHAPTER 9: COMPANY PROFILES

9.1. Novartis AG
- 9.1.1. Company Overview
- 9.1.2. Key Executives
- 9.1.3. Company Snapshot
- 9.1.4. Operating Business Segments
- 9.1.5. Product Portfolio
- 9.1.6. Business Performance
- 9.1.7. Key Strategic Moves and Developments
9.2. Eli Lilly And Company
- 9.2.1. Company Overview
- 9.2.2. Key Executives
- 9.2.3. Company Snapshot
- 9.2.4. Operating Business Segments
- 9.2.5. Product Portfolio
- 9.2.6. Business Performance
- 9.2.7. Key Strategic Moves and Developments
9.3. Abbott Laboratories
- 9.3.1. Company Overview
- 9.3.2. Key Executives
- 9.3.3. Company Snapshot
- 9.3.4. Operating Business Segments
- 9.3.5. Product Portfolio
- 9.3.6. Business Performance
- 9.3.7. Key Strategic Moves and Developments
9.4. Endo Health Solutions, Inc.
- 9.4.1. Company Overview
- 9.4.2. Key Executives
- 9.4.3. Company Snapshot
- 9.4.4. Operating Business Segments
- 9.4.5. Product Portfolio
- 9.4.6. Business Performance
- 9.4.7. Key Strategic Moves and Developments
9.5. Purdue Pharma L.P.
- 9.5.1. Company Overview
- 9.5.2. Key Executives
- 9.5.3. Company Snapshot
- 9.5.4. Operating Business Segments
- 9.5.5. Product Portfolio
- 9.5.6. Business Performance
- 9.5.7. Key Strategic Moves and Developments
9.6. Pfizer, Inc.
- 9.6.1. Company Overview
- 9.6.2. Key Executives
- 9.6.3. Company Snapshot
- 9.6.4. Operating Business Segments
- 9.6.5. Product Portfolio
- 9.6.6. Business Performance
- 9.6.7. Key Strategic Moves and Developments
9.7. Viatris Inc.
- 9.7.1. Company Overview
- 9.7.2. Key Executives
- 9.7.3. Company Snapshot
- 9.7.4. Operating Business Segments
- 9.7.5. Product Portfolio
- 9.7.6. Business Performance
- 9.7.7. Key Strategic Moves and Developments
9.8. Merck And Co. Inc.
- 9.8.1. Company Overview
- 9.8.2. Key Executives
- 9.8.3. Company Snapshot
- 9.8.4. Operating Business Segments
- 9.8.5. Product Portfolio
- 9.8.6. Business Performance
- 9.8.7. Key Strategic Moves and Developments
9.9. Johnson And Johnson
- 9.9.1. Company Overview
- 9.9.2. Key Executives
- 9.9.3. Company Snapshot
- 9.9.4. Operating Business Segments
- 9.9.5. Product Portfolio
- 9.9.6. Business Performance
- 9.9.7. Key Strategic Moves and Developments
9.10. GlaxoSmithKline Plc
- 9.10.1. Company Overview
- 9.10.2. Key Executives
- 9.10.3. Company Snapshot
- 9.10.4. Operating Business Segments
- 9.10.5. Product Portfolio
- 9.10.6. Business Performance
- 9.10.7. Key Strategic Moves and Developments